$AKRO announced publication of Phase 2b SYMMETRY Cohort D expansion study results indicating potential of #EFX to improve resolution of steatohepatitis & fibrosis for patients with #MASH & #T2D taking a GLP-1 receptor agonist: bit.ly/49Y9vai. #LiverTwitter #NASH

$AKRO announces closing of public offering of common stock & full exercise of underwriters' option to purchase additional shares: bitly.ws/3fzx8

We celebrate the FDA approval of REZDIFFRA. MASH represents a substantial health concern for which there were no approved treatments—until today. This milestone signals continued progress toward additional treatment options that directly address patient needs. #LiverTwitter

#MASH, a severe form of metabolic dysfunction-associated steatotic liver disease, is on the rise worldwide. This #WorldLiverDay, let’s prioritize liver health and the pressing need for diverse treatment solutions. #GlobalHealth #LiverHealth #LiverTwitter

$AKRO is pleased to announce the appointment of CMC veteran Scott Gangloff as #ChiefTechnologyOfficer who will play a vital role as #EFX advances through late stage clinical development. Learn more bit.ly/3xYX5Bs #TeamAkero #biotechnology #LiverTwitter #CTO #MASH

Join $AKRO next week at the BofA Securities 2024 Health Care Conference for a live webcast of our corporate presentation on Tuesday, May 14 at 5PM PT. Learn more: bit.ly/4b3bI5g. #BofASecurities #LiverTwitter

Join $AKRO next week at the Jefferies Global Healthcare Conference for a live webcast of our corporate presentation on Wednesday, June 5 at 4PM ET. Learn more: bit.ly/3X6ftD3. #JefferiesHealthcare #LiverTwitter

$AKRO is excited to be at #EASLCongress 2024! We will share a late-breaking presentation of Week 96 results from the Ph 2b HARMONY study and a post-hoc biomarker analysis demonstrating the anti-fibrotic effects of #EFX in patients with F2-F3 fibrosis due to MASH. #LiverTwitter

Our Finance team had a blast together at an asylum themed escape room last week. Collaborating to solve challenges is what #TeamAkero is all about!

Don’t miss our #efruxifermin presentations tomorrow at the #EASLCongress! #LiverTwitter #EFX $AKRO

$AKRO announced today two #EFX updates at #EASLCongress: a late-breaking analysis of Week 96 results of the Ph 2b HARMONY trial and a post-hoc biomarker analysis showing the anti-fibrotic effects of EFX in patients with #MASH fibrosis F2-F3. Learn more: bit.ly/4ehnFGr

$AKRO announced today the initiation of SYNCHRONY Outcomes, the third study in our Phase 3 trial program evaluating the efficacy and safety of #EFX in patients with compensated cirrhosis (F4) due to #MASH. Read more: bit.ly/3ViFIn5. #ClinicalTrials #LiverTwitter

Akero joins @globalliver on Global #fattyliverday to raise awareness about #MASLD and its more severe form #MASH, a serious condition that can be life-threatening. 👉Learn more about the importance of screening & education: globalfattyliverday.com #ActNowScreenToday #LiverTwitter

Mark your calendars for our oral presentation at #ECM2024 on Wednesday where Erik Tillman will share data on the effects of #EFX on remodeling the extracellular matrix in the liver of patients with F2-F3 MASH. #LiverTwitter $AKRO

Happy #4thofJuly from Akero! 🎆 #IndependenceDay

Today $AKRO reported Q2 2024 financial results and provided business updates. Read more at: ir.akerotx.com/news-releases/…

Mark your calendars for Akero’s upcoming presentation at the Morgan Stanley Annual Global Healthcare Conference next Wednesday. A live webcast will be available through the investors/events & presentations section of our website. Learn more: ir.akerotx.com/news-releases/…

#MASH is a severe liver disease that can lead to scarring and liver failure. Our Ph 3 #SYNCHRONY program is assessing investigational drug #EFX in patients with MASH. Learn more from this Liver Disease News article detailing our approach and how to qualify: liverdiseasenews.com/news/fatty-liv…

Akero announced the first patient was dosed in the Phase 3 SYNCHRONY Outcomes #ClinicalTrial evaluating EFX for the treatment of compensated cirrhosis due to #MASH. Read more here: ir.akerotx.com/news-releases/…